499 results on '"Schönland, Stefan"'
Search Results
2. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT
3. Light chain mutations contribute to defining the fibril morphology in systemic AL amyloidosis
4. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders
5. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
6. An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT
7. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
8. Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis
9. First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma
10. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
11. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT
12. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
13. Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT
14. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT
15. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
16. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia
17. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
18. A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis
19. Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis
20. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval.
21. HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients.
22. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
23. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
24. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
25. Search for AL amyloidosis risk factors using Mendelian randomization
26. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
27. Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation
28. Impaired in vitro growth response of plasma-treated cardiomyocytes predicts poor outcome in patients with transthyretin amyloidosis
29. Solid state NMR assignments of a human λ-III immunoglobulin light chain amyloid fibril
30. Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT
31. Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma.
32. Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis.
33. Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT
34. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis
35. Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM
36. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
37. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis
38. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance
39. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
40. Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT)
41. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
42. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma
43. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
44. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
45. Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era
46. AL amyloidosis with a localized B cell neoplasia
47. Local vs. systemic pulmonary amyloidosis—impact on diagnostics and clinical management
48. Comparison of Different Stem Cell Mobilization Regimens in AL Amyloidosis Patients
49. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT
50. CMR 3-102 - Machine Learning Can Distinguish Hypertrophic Cardiomyopathy, Cardiac Light Chain and Transthyretin Amyloidosis Using Cardiac Magnetic Resonance Imaging Data and Standard Clinical Information
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.